Beta
Trial Radar KI
Die klinische Studie NCT07494526 für Chronic Kidney Diease, Diabetes mellitus, Hypertonie, Hyperlipidämie, Hyperurikämie ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

Chronic Kidney Disease and Metabolic Disorders in the Elderly 100.000 Senioren Beobachtend

Noch nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07494526 ist eine beobachtungsstudie zur Untersuchung von Chronic Kidney Diease, Diabetes mellitus, Hypertonie, Hyperlipidämie, Hyperurikämie und hat den Status noch nicht rekrutierend. Der Start ist für 1. April 2026 geplant, bis 100.000 Teilnehmer aufgenommen werden. Durchgeführt von Chinese PLA General Hospital wird der Abschluss für 1. Dezember 2028 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. März 2026 aktualisiert.
Kurzbeschreibung
The goal of this observational study is to investigate the impact of metabolic comorbidities on outcomes in elderly Chinese adults, through two parallel sub-cohorts: one comprising elderly individuals without chronic kidney disease (CKD) at baseline, and one comprising elderly patients with established CKD.

The main questions it aims to answer are:

Do metabolic diseases (diabetes, hypertension, hyperlipidemia, hype...

Mehr anzeigen
Ausführliche Beschreibung
Background and Rationale Chronic kidney disease (CKD) complicated by metabolic disorders - including diabetes mellitus, hypertension, hyperlipidemia, hyperuricemia, and calcium-phosphorus disturbances - poses a significant public health threat to the elderly population. China is experiencing accelerating demographic aging, making the burden of CKD and metabolic comorbidity in older adults an increasingly pressing cli...Mehr anzeigen
Offizieller Titel

Research on the Prevention, Control, and Intelligent Management Decision-Making for Comorbidities of Chronic Kidney Disease and Metabolic Disorders in the Elderly

Erkrankungen
Chronic Kidney DieaseDiabetes mellitusHypertonieHyperlipidämieHyperurikämie
Publikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:
Weitere Studien-IDs
  • 2024YFC3607400
  • 2024YFC3607400 (Andere Zuwendungs-/Finanzierungsnummer) (National Key Research and Development Program of China)
NCT-Nummer
Studienbeginn (tatsächlich)
2026-04
Zuletzt aktualisiert
2026-03-27
Studienende (vorauss.)
2028-12
Geplante Rekrutierung
100.000
Studientyp
Beobachtungsstudie
Status
Noch nicht rekrutierend
Stichwörter
chronic kidney disease
elderly
metabolic disorders
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Sub-cohort 1 - Elderly Adults without chronic kidney disease (CKD) at Baseline
Nicht zutreffend
Sub-cohort 2 - Elderly Patients with chronic kidney disease (CKD)
Nicht zutreffend
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
incident CKD
For Sub-cohort 1 in Elderly Adults without CKD at Baseline, the primary outcome is incident CKD, which is defined as glomerular filtration rate (eGFR) \< 60 ml/(min·1.73m²) or positive urine protein; or the presence of a clear ICD-10 diagnostic code for CKD in medical records.
through study completion, an average of 1 year
All-cause mortality
From date of enrollment until death from any cause, assessed up to 5 years
Progression to ESRD.
From date of enrollment until progression to ESRD or death from any cause, whichever came first, assessed up to 5 years
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Ältere Erwachsene
Mindestalter
65 Years
Zugelassene Geschlechter
Alle
Akzeptiert gesunde Freiwillige
Ja
EXCLUSION CRITERIA:

INCLUSION CRITERIA:

  1. Baseline age ≥ 65 years.
  2. Availability of baseline data on serum creatinine and at least one urinary protein measurement.
  3. Urinary protein measurements include: UACR, UPCR, 24-hour urine protein quantification, and urine protein dipstick test.
  4. Baseline date requirement: Between January 1, 2010, and December 31, 2025.
  5. Follow-up requirement meeting at least one of the following: At least one serum creatinine measurement with an interval of ≥ 6 months after baseline. Occurrence of a primary endpoint event (new-onset CKD).

Exclusion Criteria:

Presence of CKD at baseline, defined as: Glomerular filtration rate (eGFR) < 60 ml/(min·1.73m²) or positive urine protein; or the presence of an ICD-10 diagnostic code for CKD in medical records.

For Sub-cohort 2 (CKD Patients), the inclusion and exclusion criteria are as follows:

Inclusion Criteria:

  1. Baseline age ≥ 65 years.
  2. Meeting the diagnostic criteria for CKD: Glomerular filtration rate (eGFR) < 60 ml/(min·1.73m²) or urine protein (UACR ≥ 30 mg/g); or based on ICD-10 codes.
  3. Baseline date requirement: Between January 1, 2010, and December 31, 2025.
  4. Follow-up requirement meeting at least one of the following:

Occurrence of a primary endpoint event (mortality, ESRD); At least one serum creatinine measurement with an interval of ≥ 6 months after baseline.

Exclusion Criteria:

  1. End-stage renal disease (ESRD) at baseline (eGFR < 15 ml/(min·1.73m²), or prior receipt of kidney transplant or dialysis), based on ICD codes).
  2. Diagnosis of acute kidney injury (AKI) within the preceding 3 months.
  3. New York Heart Association (NYHA) Class III or IV heart failure or occurrence of acute myocardial infarction within the preceding 6 months.
  4. Child-Pugh Class B or C liver cirrhosis.
  5. Malignant neoplasm.
Chinese PLA General Hospital logoChinese PLA General Hospital
Verantwortliche Partei
Yuanjun Yang, Hauptprüfer, Principal Investigator, Chinese PLA General Hospital
Zentrale Studienkontakte
Kontakt: Shuang Liang, 86+15110246423, [email protected]
2 Studienstandorte in 1 Ländern

Beijing Municipality

Chinese PLA General Hospital, Beijing, Beijing Municipality, 100853, China
chinese PLA general hospital, Beijing, Beijing Municipality, 100853, China
Shuang Liang, PhD, Kontakt, 86+15110246423, [email protected]
Yisha Li, PhD, Kontakt, 86+18911772124, [email protected]